Philadelphia-based Virpax Pharmaceuticals has licensed an asset, AnQlar, that has potential to be an OTC treatment for COVID-19.
Pain Management Company Virpax Sees Promise in Potential COVID-19 Antiviral OTC

Philadelphia-based Virpax Pharmaceuticals has licensed an asset, AnQlar, that has potential to be an OTC treatment for COVID-19.